Irish company purchases Aptiv Solutions

Irish company ICON plc has agreed to buy Reston-based Aptiv Solutions for $143.5 million.

Aptiv Solutions designs and executes clinical trials for pharmaceutical and biotech customers. The company has operations in 16 countries.

Aptiv’s ADDPLAN software supports the design and analysis for adaptive trials used by the Federal Drug Administration, European Medicines Agency, Japan’s Pharmaceuticals and Medical Devices Agency and more than 50 top pharmaceutical and medical device companies and academic researchers.

Aptiv also owns Niphix, an oncology-focused research organization that has both Japanese and international customers. This will be combined with ICON’s current operations in Tokyo and Osaka.

“Aptiv Solutions’ adaptive trial capabilities will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier,”  Dr. Nuala Murphy, president, ICON Clinical Research Services, said in a statement. “Their presence in Japan will also broaden our existing capabilities in this market.”

ICON provides development services to the pharmaceutical, biotechnology and medical device industries. ICON currently has approximately 10,300 employees, operating from 77 locations in 38 countries.